JP7410017B2 - 新規なテトラゾール化合物および結核の治療におけるそれらの使用 - Google Patents
新規なテトラゾール化合物および結核の治療におけるそれらの使用 Download PDFInfo
- Publication number
- JP7410017B2 JP7410017B2 JP2020508427A JP2020508427A JP7410017B2 JP 7410017 B2 JP7410017 B2 JP 7410017B2 JP 2020508427 A JP2020508427 A JP 2020508427A JP 2020508427 A JP2020508427 A JP 2020508427A JP 7410017 B2 JP7410017 B2 JP 7410017B2
- Authority
- JP
- Japan
- Prior art keywords
- tetrazol
- benzenesulfonamide
- hydroxyethyl
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382574.6 | 2017-08-17 | ||
| EP17382574 | 2017-08-17 | ||
| PCT/EP2018/072205 WO2019034729A1 (en) | 2017-08-17 | 2018-08-16 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531425A JP2020531425A (ja) | 2020-11-05 |
| JP2020531425A5 JP2020531425A5 (enExample) | 2021-09-24 |
| JP7410017B2 true JP7410017B2 (ja) | 2024-01-09 |
Family
ID=59713960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508427A Active JP7410017B2 (ja) | 2017-08-17 | 2018-08-16 | 新規なテトラゾール化合物および結核の治療におけるそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11072591B2 (enExample) |
| EP (1) | EP3668856B1 (enExample) |
| JP (1) | JP7410017B2 (enExample) |
| KR (1) | KR102661367B1 (enExample) |
| CN (1) | CN110997651B (enExample) |
| AU (1) | AU2018317812C1 (enExample) |
| CA (1) | CA3072854A1 (enExample) |
| CY (1) | CY1124577T1 (enExample) |
| DK (1) | DK3668856T3 (enExample) |
| ES (1) | ES2885573T3 (enExample) |
| HR (1) | HRP20211326T1 (enExample) |
| HU (1) | HUE055732T2 (enExample) |
| LT (1) | LT3668856T (enExample) |
| PL (1) | PL3668856T3 (enExample) |
| PT (1) | PT3668856T (enExample) |
| RS (1) | RS62267B1 (enExample) |
| SI (1) | SI3668856T1 (enExample) |
| SM (1) | SMT202100515T1 (enExample) |
| WO (1) | WO2019034729A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184718A (zh) * | 2018-11-15 | 2020-05-22 | 鲁南制药集团股份有限公司 | 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途 |
| CN115403533B (zh) * | 2021-05-28 | 2023-08-25 | 永康市第一人民医院 | 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用 |
| CN116102483B (zh) * | 2021-11-09 | 2025-01-17 | 中国医学科学院药物研究所 | 取代吡咯-2,5-二酮类化合物及其制备方法和用途 |
| CN116726018A (zh) * | 2023-08-02 | 2023-09-12 | 上海市肺科医院（上海市职业病防治院） | 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用 |
| CN117379430B (zh) * | 2023-10-11 | 2026-07-21 | 深圳市第三人民医院(深圳市肝病研究所) | 一种地拉韦啶的用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999004780A1 (en) | 1997-07-22 | 1999-02-04 | Shionogi & Co., Ltd. | Therapeutic or prophylactic agent for glomerulopathy |
| WO2017066964A1 (en) | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523599A (ja) | 2007-04-05 | 2010-07-15 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | クリックケミストリーを使用した炭酸脱水酵素−ｉｘのための分子イメージングプローブの開発 |
-
2018
- 2018-08-16 HU HUE18755815A patent/HUE055732T2/hu unknown
- 2018-08-16 PL PL18755815T patent/PL3668856T3/pl unknown
- 2018-08-16 CA CA3072854A patent/CA3072854A1/en active Pending
- 2018-08-16 HR HRP20211326TT patent/HRP20211326T1/hr unknown
- 2018-08-16 JP JP2020508427A patent/JP7410017B2/ja active Active
- 2018-08-16 SM SM20210515T patent/SMT202100515T1/it unknown
- 2018-08-16 KR KR1020207007186A patent/KR102661367B1/ko active Active
- 2018-08-16 WO PCT/EP2018/072205 patent/WO2019034729A1/en not_active Ceased
- 2018-08-16 EP EP18755815.0A patent/EP3668856B1/en active Active
- 2018-08-16 AU AU2018317812A patent/AU2018317812C1/en active Active
- 2018-08-16 LT LTEPPCT/EP2018/072205T patent/LT3668856T/lt unknown
- 2018-08-16 RS RS20211076A patent/RS62267B1/sr unknown
- 2018-08-16 ES ES18755815T patent/ES2885573T3/es active Active
- 2018-08-16 SI SI201830348T patent/SI3668856T1/sl unknown
- 2018-08-16 DK DK18755815.0T patent/DK3668856T3/da active
- 2018-08-16 CN CN201880053320.XA patent/CN110997651B/zh active Active
- 2018-08-16 US US16/639,163 patent/US11072591B2/en active Active
- 2018-08-16 PT PT187558150T patent/PT3668856T/pt unknown
-
2021
- 2021-08-31 CY CY20211100770T patent/CY1124577T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999004780A1 (en) | 1997-07-22 | 1999-02-04 | Shionogi & Co., Ltd. | Therapeutic or prophylactic agent for glomerulopathy |
| WO2017066964A1 (en) | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
Also Published As
| Publication number | Publication date |
|---|---|
| PT3668856T (pt) | 2021-09-15 |
| CA3072854A1 (en) | 2019-02-21 |
| PL3668856T3 (pl) | 2021-12-13 |
| SI3668856T1 (sl) | 2021-11-30 |
| US20200231555A1 (en) | 2020-07-23 |
| KR102661367B1 (ko) | 2024-04-29 |
| BR112020003247A2 (pt) | 2020-08-18 |
| CN110997651B (zh) | 2023-01-03 |
| CN110997651A (zh) | 2020-04-10 |
| RS62267B1 (sr) | 2021-09-30 |
| LT3668856T (lt) | 2021-09-27 |
| RU2020110818A3 (enExample) | 2021-10-11 |
| KR20200041915A (ko) | 2020-04-22 |
| AU2018317812C1 (en) | 2021-08-26 |
| EP3668856B1 (en) | 2021-06-23 |
| CY1124577T1 (el) | 2022-07-22 |
| AU2018317812A1 (en) | 2020-02-20 |
| AU2018317812B2 (en) | 2021-04-15 |
| HUE055732T2 (hu) | 2021-12-28 |
| RU2020110818A (ru) | 2021-09-17 |
| ES2885573T3 (es) | 2021-12-14 |
| US11072591B2 (en) | 2021-07-27 |
| EP3668856A1 (en) | 2020-06-24 |
| HRP20211326T1 (hr) | 2021-11-26 |
| WO2019034729A1 (en) | 2019-02-21 |
| JP2020531425A (ja) | 2020-11-05 |
| DK3668856T3 (da) | 2021-09-20 |
| SMT202100515T1 (it) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102661367B1 (ko) | 신규 테트라졸 화합물 및 결핵의 치료에서의 그의 용도 | |
| US10221162B2 (en) | Triazole agonists of the APJ receptor | |
| EP3191478B1 (en) | Compounds and compositions as raf kinase inhibitors | |
| US9694016B2 (en) | Biaryl amide compounds as kinase inhibitors | |
| JP6308504B2 (ja) | タンパク質キナーゼ阻害薬 | |
| US11427558B1 (en) | Indazoles and azaindazoles as LRRK2 inhibitors | |
| WO2011147259A1 (zh) | 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 | |
| EA033758B1 (ru) | 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина | |
| EP2411368A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux | |
| WO2021064677A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| RU2800930C2 (ru) | Новые производные тетразола и их применение в лечении туберкулеза | |
| BR112020003247B1 (pt) | Compostos de tetrazol, uso dos ditos compostos para o tratamento de infecção micobacteriana ou de doença causada pela mesma, composição farmacêutica e combinação que compreende os compostos | |
| JP2025513725A (ja) | Ｔｅａｄ阻害剤および使用方法 | |
| CN121712766A (zh) | 吗啉促食欲素受体拮抗剂 | |
| HK40039580A (en) | Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria | |
| HK40072544A (en) | Hepatitis b core protein allosteric modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210816 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210816 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230406 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231010 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231221 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7410017 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |